NasdaqCM - Nasdaq Real Time Price • USD
aTyr Pharma, Inc. (LIFE)
As of 9:41 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 4 |
Avg. Estimate | -0.24 | -0.24 | -0.94 | -0.95 |
Low Estimate | -0.29 | -0.3 | -1.19 | -1.11 |
High Estimate | -0.18 | -0.19 | -0.75 | -0.64 |
Year Ago EPS | -0.29 | -0.22 | -0.94 | -0.94 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 4 |
Avg. Estimate | 20k | 20k | 2.16M | 9.26M |
Low Estimate | -- | -- | -- | -- |
High Estimate | 100k | 100k | 10M | 24.43M |
Year Ago Sales | 300k | -- | 353k | 2.16M |
Sales Growth (year/est) | -93.30% | -- | 511.90% | 328.70% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.4 | -0.28 | -0.23 | -0.24 |
EPS Actual | -0.29 | -0.22 | -0.2 | -0.25 |
Difference | 0.11 | 0.06 | 0.03 | -0.01 |
Surprise % | 27.50% | 21.40% | 13.00% | -4.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.24 | -0.24 | -0.94 | -0.95 |
7 Days Ago | -0.24 | -0.24 | -0.94 | -0.95 |
30 Days Ago | -0.24 | -0.24 | -0.94 | -0.95 |
60 Days Ago | -0.21 | -0.21 | -0.85 | -0.95 |
90 Days Ago | -0.21 | -0.21 | -0.85 | -0.95 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | LIFE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 17.20% | -- | -- | 1.50% |
Next Qtr. | -9.10% | -- | -- | 12.10% |
Current Year | 0.00% | -- | -- | 4.40% |
Next Year | -1.10% | -- | -- | 13.20% |
Next 5 Years (per annum) | 13.00% | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | RBC Capital: Outperform to Outperform | 3/15/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 9/21/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 9/14/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
Related Tickers
MREO Mereo BioPharma Group plc
2.7750
-1.25%
SCPH scPharmaceuticals Inc.
4.3400
-0.23%
KZR Kezar Life Sciences, Inc.
0.7973
+0.92%
MDNAF Medicenna Therapeutics Corp.
1.4000
0.00%
LPTX Leap Therapeutics, Inc.
3.2600
+2.85%
RLMD Relmada Therapeutics, Inc.
3.6950
-0.13%
CNSP CNS Pharmaceuticals, Inc.
0.2049
-1.92%
CLRB Cellectar Biosciences, Inc.
3.0399
+0.66%
GLYC GlycoMimetics, Inc.
1.6900
-1.17%
MIST Milestone Pharmaceuticals Inc.
1.5797
-0.65%